Latest Research And Development News

Environmental Clean Technologies (ASX: ECT) disclosed confidential talks on acquiring Xenica Materials and a new engineering deal with Metallium amid a price surge, followed by a $12 million placement announcement.

IperionX plans to relocate its parent company to Texas and list directly on Nasdaq, aligning its corporate structure with its US operations. The appointment of manufacturing veteran Michael J. Loparco aims to bolster the company’s industrial scale-up.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

Spenda Limited has reshaped its business with significant cost cuts, divested non-core assets, and secured major shareholder backing, positioning itself for cash flow positive operations.

ClearVue Technologies bolstered its balance sheet with a A$6 million capital raise while landing high-profile projects including Canva’s Sydney HQ and its first European contract in Cyprus. The company also advanced international expansion and achieved key certifications confirming product durability and safety.

Nexus Minerals has completed nearly 22,000m of RC drilling at Wallbrook, delivering strong gold intercepts and setting up an updated resource estimate by September. The company also moved to acquire Northern Star's remaining 10% stake in the Pinnacles JV, consolidating full ownership.

Jindalee Lithium is pushing ahead with its McDermitt Lithium Project in the US, securing shareholder approval for a NASDAQ listing via US Elemental and raising $10.9 million to fund drilling and testwork. The project aims to deliver both lithium and magnesium, aligning with US critical minerals priorities.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.